Metabolomics Characterization of Biomarkers of ASCVD and Prediction Model
NCT ID: NCT05148182
Last Updated: 2021-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1869 participants
OBSERVATIONAL
2021-12-15
2024-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. Establish accurate prediction model of atherosclerotic heart disease.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Therefore, the aim of this study was to
1.Describe the risk factors of atherosclerotic cardiovascular disease and the characteristics of metabolomics in Chinese population.
2\. Establish an accurate prediction model of atherosclerotic heart disease. Research plan：
1. 1869 risk-stratified people were recruited.
2. Plasma samples were collected incluing disease status and other potential influencing factors.
3. Through the high-throughput detection of body metabolites, combined with multivariate statistical analysis, the metabolic markers with significant difference in different risk levels were screened for risk prediction.
4. All recruited people underwent coronary angiography.
5. The distribution of age and gender in each group should be matched and balanced as far as possible.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
low risk
According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as low-risk population.
No interventions assigned to this group
medium risk
According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as medium-risk population.
No interventions assigned to this group
high risk
According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as high-risk population.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. According to China PAR equations, Chinese guidelines and consensus on cardiovascular risk assessment and management，it is considered as healthy, low, medium, high and extremely high risk group.
3. The subjects read and fully understood the patient's instructions and signed the informed consent
Exclusion Criteria
2. ACS is caused by surgery, trauma, or other diseases.
3. Age less than 18 years old.
4. Pregnant women.
5. In the past 3 months, the patients were treated with trauma surgery.
6. There are aortic dissection, pulmonary embolism, pneumonia, pericarditis, myocarditis, stress cardiomyopathy.
7. Severe heart failure.
8. Liver and kidney failure.
9. Blood borne infectious diseases: including HIV / AIDS, hepatitis B, hepatitis C, etc.
10. Patients with a history of malignancies, autoimmune diseases, severe infectious diseases and trauma.
11. Any condition (such as travel, speech disorder, mental disorder) that the researcher believes can significantly limit the completion of the patient's follow-up.
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai 10th People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ya-Wei Xu
Chief Physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology,Shanghai Tenth People's Hospital
Shanghai, , China
Shanghai Tenth People's Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yan Cang, doctor
Role: primary
Yawei Xu, PhD
Role: backup
yan cang, doctor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MEAL
Identifier Type: -
Identifier Source: org_study_id